---

Platinum Opinions

25

KIUrologyX: Urology As You Like It—A Massive Open Online Course for Medical Students, Professionals, Patients, and Laypeople Alike

25

Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer

27

The New US Preventive Services Task Force “C” Draft Recommendation for Prostate Cancer Screening

30

Brief Correspondence

33

Quantified Clinical Risk Change as an End Point During Prostate Cancer Active Surveillance

33

Platinum Priorities

37

Partial Prostatectomy for Anterior Cancer: Short-term Oncologic and Functional Outcomes

37

Prostate Cancer

47

Je le pansai, Dieu le guerit

47

Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy

49

Local Therapy for Disseminated Prostate Cancer: Improved Outcomes or Biased Confounders?

56

Urothelial Cancer

58

Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset

58

Seeking the Molecular Truth in Bladder Cancer: Biology = Genome × (Transcriptome)²

70

Kidney Cancer

72

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

72

RECISTing the Temptation to Prematurely Stop Nivolumab

81

The Impact of Quality Variations on Patients Undergoing Surgery for Renal Cell Carcinoma: A National Cancer Database Study

83

Improving Quality in Renal Cell Carcinoma Care: Bridging the Gap Between Measurement and Meaning

91

Incontinence

93

Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice

93

Better Persistence Rates with Mirabegron: Questions Raised

104

Voiding Dysfunction

106

Qualitative Exploration of the Patient Experience of Underactive Bladder

106

Towards a Greater Understanding of Underactive Bladder

112

Reply from Authors re: Mikkel Fode, Jens Sønksen. Towards a Greater Understanding of Underactive Bladder. Eur Urol 2017;72:408–9

113

Reviews

115

Urothelial Cancer

115

Systematic Review of Immune Checkpoint Inhibition in Urological Cancers

115

Incontinence

128

Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence

128

Surgery in Motion

136

Robot-assisted Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer

136

Salvage Surgery for Nodal Recurrence of Prostate Cancer: Might the Robotic Approach Render an Experimental Procedure More Acceptable?

143

Original Articles

146

Prostate Cancer

146

Adverse Disease Features in Gleason Score 3 4 “Favorable Intermediate-Risk” Prostate Cancer: Implications for Active Surveillance

146

Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study

152

Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 Prostate Cancer

159

Bladder Cancer

165

Prognostic Impact of a 12-gene Progression Score in Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study

165

Words of Wisdom

174

Re: 10-Year Outcomes After Monitoring, Surgery or Radiotherapy for Localized Prostate Cancer

174

Re: Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer

174

Re: Radiation with or Without Antiandrogen Therapy in Recurrent Prostate Cancer

175

Re: Lower Urinary Tract Symptoms and Incident Falls in Community Dwelling Older Men: The Concord Health and Ageing in Men Project

176

Re: Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma

177

Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement

178

Letters to the Editor published online

181

Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606–17

181

Reply to Lorenzo Marconi, Steven MacLennan, Thomas B.L. Lam, et al’s Letter to the Editor re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606–17

183

Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952–60. Methodological Issues to Avoid Misinterpretation

185

Reply to Saeid Safiri and Erfan Ayubi’s Letter to the Editor re: Nicholas J. Giacalone, e64William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After BladderpreservingTri-modality Therapy for Patients with Muscle-invasive Bladder Cancer:An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol2017;71:952–60. Methodological Issues to Avoid Misinterpretation

186

Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. “Gotta Catch ‘em All” or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1–3.

188

Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838–40. Clinical Utility of Trial-estimated Prognostic Models

190

Reply to Tuomas Mirtti and Tero Aittokallio’s Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838–40. Clinical Utility of Trial-estimated Prognostic Models

192

Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405–14

194

Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen’s Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405–14

196

Congress Calendar

198

Corrigendum re: “Early Recurrence Patterns Following Totally Intracorporeal Robot-assisted Radical Cystectomy: Results from the EAU Robotic Urology Section (ERUS) Scientific Working Group” [Eur Urol 2017;71:723–6]

202

Corrigendum re: “Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial” [Eur Urol 2015;68:216–25]

203